Dermatophagoides pteronyssinus



Dermatophagoides pteronyssinus is an extract from Dermatophagoides pteronyssinus used in allergy testing.

Brand Names
Acarizax, Odactra
Generic Name
Dermatophagoides pteronyssinus
DrugBank Accession Number

Dermatophagoides pteronyssinus extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.

Biologic Classification
Allergen Extract
  • AE-mite, dermatophagoides pteronyssinus
  • Dermatophagoides pteronyssinus whole
  • European house dust mite
  • European house dust mite extract
  • House dust mite extract, dermatophagoides pteronyssinus
  • Insects (whole body), mite dermatophagoides pteronyssinus
  • Mite D.P.
  • Mite D.P. (dermatophagoides pteronyssinus) standardized



Dermatophagoides pteronyssinus is indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or skin testing to licensed house dust mite allergen extracts. It is approved for use in patients 12 through 65 years of age.3

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to manageAllergic rhinitis due to house dust miteCombination Product in combination with: Dermatophagoides farinae (DB10400)••••••••••••••••••••••••••• ••••• •••• •••• •••••••••••••
Used in combination to manageAllergic rhinitis due to house dust miteCombination Product in combination with: Dermatophagoides farinae (DB10400)••••••••••••••••• •••• •••• •••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more

Treatment with ACTAIR has been shown to induce a systemic antibody response towards house dust mite allergens, with an increase in specific IgG4 antibodies in some patients. These immunoglobulins may compete with IgE for allergen binding, thereby decreasing allergen capture and presentation.

Mechanism of action

The complete mechanisms of allergen immunotherapy are not clear and remain the subject of investigation. The allergic reaction is dependent on the presence of allergen-specific immunoglobulin E (IgE) antibodies that are bound to specific receptors on mast cells and basophils. The presence of IgE antibodies sensitizes these cells, and upon interaction with the appropriate allergens, histamine and other mediators are released which produce local or systemic responses in sensitive individuals, and characteristic symptoms of atopic diseases, such as allergic rhinitis and allergic asthma. Changes in serum antibody and T-lymphocyte responses resulting from immunotherapy have been demonstrated, and these changes often correlate closely with clinical (symptom) improvements. Specific mechanisms may vary depending on the nature of the allergic disease, the allergenic specificities of patients and populations, extract formulations, route of administration, dose and duration of treatment. Subcutaneous administration of allergenic extracts is known to elicit numerous immunological changes that are both time and dose-dependent. Many of these changes appear to be related to (or a precursor to) improvements in symptoms and other clinical parameters, as noted above. Specific changes found after immunotherapy with dust mite extracts include significant increases in mite-specific IgG4 antibodies, interleukin-10-positive T cells, and several T-cell receptors, and significant decreases in serum nitric oxide, eosinophil catonic protein, interleukin-4-positive T cells and IgE-mediated basophil histamine release.


Allergens in ACTAIR consist mainly of proteins and glycoproteins. There is no direct bioavailability of intact allergens in the blood. Therefore, no pharmacokinetic studies in animals or in humans have been carried out to investigate the pharmacokinetic profile and metabolism of ACTAIR.

Volume of distribution

Not Available

Protein binding

Not Available

Not Available
Route of elimination

Not Available


Not Available


Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample

Not Available

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Allergen Pack Dermatophagoides PteronyssinusSolution10000 [AU]/1mLIntradermal; SubcutaneousAlvix Laboratories2015-06-252018-03-08US flag
Allergenic Extract - Standardized Mite Dermatophagoides PteronyssinusLiquid10000 unit / mLIntradermal; SubcutaneousGreer Laboratories1999-03-15Not applicableCanada flag
Allergenic Extract - Standardized Mite Dermatophagoides PteronyssinusLiquid5000 unit / mLIntradermal; SubcutaneousGreer LaboratoriesNot applicableNot applicableCanada flag
Allergenic Extract Standardized Mite DpLiquid10000 unit / mLSubcutaneousHollister Stier, Unit Pharm, Division Of Miles Canada Inc.1992-12-311998-09-25Canada flag
Allergenic Extract Standardized Mite DpLiquid30000 unit / mLSubcutaneousHollister Stier, Unit Pharm, Division Of Miles Canada Inc.1992-12-311998-09-25Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AcarizaxDermatophagoides pteronyssinus (6 unit) + Dermatophagoides farinae (6 unit)TabletSublingualAlk Abelló A/S2017-11-06Not applicableCanada flag
ACARIZAXDermatophagoides pteronyssinus (6 AU) + Dermatophagoides farinae (6 AU)PowderOralบริษัท แอ๊บบอต ลาบอแรตอรีส จำกัด2018-03-28Not applicableThailand flag
ACARIZAX 12 SQ-HDM Lyophilisat zur sublingualen AnwendungDermatophagoides pteronyssinus (12 SQ-HDM) + Dermatophagoides farinae (12 SQ-HDM)PowderOralAlk Abelló A/S2015-11-26Not applicableAustria flag
Allergenic Extract - Standardized Mite MixDermatophagoides pteronyssinus (5000 unit / mL) + Dermatophagoides farinae (5000 unit / mL)LiquidIntradermal; SubcutaneousGreer Laboratories2002-08-20Not applicableCanada flag
Allergenic Extract Mixture Of Standardized Mites (15,000 Au/ml)Dermatophagoides pteronyssinus (15000 unit / mL) + Dermatophagoides farinae (15000 unit / mL)SolutionPercutaneous; SubcutaneousJubilant Hollisterstier Llc1998-01-16Not applicableCanada flag


ATC Codes
V01AA03 — House dust mites
Drug Categories
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

CAS number
Not Available


General References
  1. FDA label [Link]
  2. Drug information [Link]
  3. FDA Approved Drug Products: ODACTRA House Dust Mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) Allergen Extract Tablet for Sublingual Use [Link]
PubChem Substance

Clinical Trials

Clinical Trials


Not Available
Not Available
Dosage Forms
Tablet, orally disintegratingOral
SolutionIntradermal; Subcutaneous10000 [AU]/1mL
LiquidIntradermal; Subcutaneous5000 unit / mL
SolutionPercutaneous; Subcutaneous
Injection, solution10000 AU/1ml
LiquidSubcutaneous10000 unit / mL
LiquidSubcutaneous30000 unit / mL
SolutionPercutaneous; Subcutaneous10000 unit / mL
SolutionPercutaneous; Subcutaneous30000 unit / mL
LiquidIntradermal; Percutaneous; Subcutaneous
LiquidIntradermal; Percutaneous; Subcutaneous10000 unit / mL
LiquidIntradermal; Subcutaneous30000 unit / mL
Injection, suspensionSubcutaneous
InjectionCutaneous; Intradermal; Subcutaneous10000 [AU]/1mL
Injection, solutionPercutaneous; Subcutaneous10000 [AU]/1mL
Injection, solutionSubcutaneous5000 [AU]/1mL
SolutionPercutaneous10000 [AU]/1mL
ConcentrateIntradermal; Percutaneous; Subcutaneous10000 [AU]/1mL
ConcentrateIntradermal; Percutaneous; Subcutaneous30000 [AU]/1mL
ConcentrateIntradermal; Percutaneous; Subcutaneous5000 [AU]/1mL
Injection, solutionIntradermal; Subcutaneous10000 [AU]/1mL
ConcentrateIntradermal; Percutaneous; Subcutaneous
Injection, solutionSubcutaneous
LiquidIntradermal; Subcutaneous10000 unit / mL
Injection, solutionIntradermal; Subcutaneous3000 [AU]/1mL
Injection, solutionIntradermal; Subcutaneous5000 [AU]/1mL
Injection, solutionSubcutaneous10000 [AU]/1mL
Injection, solutionIntradermal30 [AU]/1mL
Injection, solutionIntradermal300 [AU]/1mL
Injection, solutionPercutaneous; Subcutaneous30000 [AU]/1mL
LiquidIntradermal; Subcutaneous
Injection, solutionPercutaneous
Injection, solutionIntradermal; Subcutaneous
Solution10000 AU/1ml
Not Available
Not Available


Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:03 / Updated at April 13, 2024 19:42